Profile data is unavailable for this security.
About the company
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
- Revenue in SEK (TTM)12.07m
- Net income in SEK-20.79m
- Incorporated2014
- Employees2.00
- LocationElicera Therapeutics ABWorld Trade Center GoteborgMassans gata 10, van 7GOETEBORG 412 51SwedenSWE
- Websitehttps://www.elicera.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XP Chemistries AB | 393.54k | -7.43m | 17.89m | 2.00 | -- | 0.5219 | -- | 45.46 | -0.2059 | -0.2059 | 0.0066 | 0.2357 | 0.0159 | 3.01 | 3.45 | 196,770.00 | -29.91 | -- | -31.74 | -- | -1,218.83 | -- | -1,887.54 | -- | 3.76 | -- | 0.00 | -- | -37.14 | -- | -1.55 | -- | -- | -- |
| Lipigon Pharmaceuticals AB | 9.33m | -20.25m | 24.03m | -- | -- | 0.9519 | -- | 2.58 | -0.3541 | -0.3541 | 0.1012 | 0.1702 | 0.2851 | -- | 0.7439 | -- | -61.91 | -314.67 | -76.67 | -426.49 | -- | -- | -217.15 | -488.14 | -- | -- | 0.00 | -- | -- | 444.44 | 67.83 | -- | -- | -- |
| Ziccum AB | 5.56m | -23.18m | 37.82m | 10.00 | -- | 4.46 | -- | 6.81 | -1.63 | -1.63 | 0.3903 | 0.5312 | 0.2749 | -- | 3.31 | 694,500.00 | -114.67 | -68.51 | -163.12 | -76.47 | -- | -- | -417.19 | -2,598.03 | -- | -- | 0.0654 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
| StenoCare A/S | 4.90m | -26.36m | 40.90m | 9.00 | -- | 1.27 | -- | 8.34 | -1.04 | -1.04 | 0.1868 | 1.01 | 0.0948 | -- | 2.07 | -- | -50.98 | -28.16 | -68.69 | -35.47 | -- | -- | -537.63 | -371.06 | 0.6143 | -6.07 | 0.2763 | -- | -16.30 | -- | -7.77 | -- | -- | -- |
| QUIA PHARMA AB (publ) | 2.36m | -13.86m | 41.72m | 8.00 | -- | 1.20 | -- | 17.68 | -2.02 | -2.02 | 0.0119 | 0.0233 | 0.0703 | -- | 21.36 | -- | -41.30 | -95.67 | -50.35 | -207.86 | 160.51 | 262.59 | -587.29 | -5,002.50 | -- | -46.79 | 0.00 | -- | -- | -- | 17.75 | -- | 47.06 | -- |
| Odi Pharma AB (publ) | 22.45m | 355.97k | 48.10m | -- | 135.10 | 21.69 | 134.00 | 2.14 | 0.0234 | 0.0234 | 1.47 | 0.1457 | 2.19 | 54.42 | 5.47 | -- | 3.48 | -35.08 | 14.86 | -44.27 | 2.07 | -- | 1.59 | -99.25 | 1.22 | 1.81 | -- | -- | 15,995.75 | -- | 105.16 | -- | -- | -- |
| Arctic Bioscience AS | 30.69m | -47.25m | 51.55m | 20.00 | -- | 0.2245 | -- | 1.68 | -1.91 | -1.91 | 1.24 | 9.27 | 0.1057 | 0.674 | 2.25 | 1,570,792.00 | -16.27 | -- | -18.44 | -- | 29.20 | -- | -153.95 | -- | 1.21 | -- | 0.0075 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| ExpreS2ion Biotech Holding AB | 8.10m | -45.37m | 56.71m | 18.00 | -- | 0.629 | -- | 7.00 | -29.54 | -29.54 | 5.47 | 42.93 | 0.0772 | -- | 6.46 | 311,461.50 | -43.23 | -63.54 | -56.21 | -75.88 | -123.56 | -1.94 | -560.27 | -524.31 | -- | -- | 0.0065 | -- | 43.07 | -0.1561 | 22.94 | -- | 19.90 | -- |
| Elicera Therapeutics AB | 12.07m | -20.79m | 69.31m | 2.00 | -- | 2.68 | -- | 5.74 | -0.9137 | -0.9137 | 0.5059 | 0.7377 | 0.3224 | -- | 12.85 | 6,035,610.00 | -55.51 | -40.06 | -79.82 | -49.74 | -- | -- | -172.21 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
| Oncozenge AB | 0.00 | -11.78m | 107.88m | -- | -- | 7.59 | -- | -- | -1.01 | -1.01 | 0.00 | 1.21 | 0.00 | -- | -- | -- | -55.08 | -- | -59.44 | -- | -- | -- | -- | -- | -- | -2,944.50 | 0.00 | -- | -- | -- | 65.91 | -- | -- | -- |
| Lipidor AB | 87.00k | -13.53m | 113.88m | -- | -- | 6.77 | -- | 1,308.93 | -0.1505 | -0.1505 | 0.0009 | 0.0207 | 0.005 | -- | 0.1843 | -- | -77.12 | -59.41 | -178.11 | -75.10 | -- | -- | -15,550.58 | -643.36 | -- | -- | 0.00 | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
| Pila Pharma AB | 1.03m | -6.92m | 130.21m | 0.00 | -- | 44.35 | -- | 125.92 | -0.3165 | -0.3165 | 0.049 | 0.1082 | 0.2602 | -- | 8.21 | 1,034,020.00 | -174.06 | -108.88 | -276.40 | -121.45 | -406.94 | -42.67 | -668.94 | -1,577.64 | -- | -163.35 | 0.00 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| Vivesto AB | 0.00 | -98.92m | 138.55m | 4.00 | -- | 0.7737 | -- | -- | -0.1839 | -0.1839 | 0.00 | 0.3328 | 0.00 | -- | -- | 0.00 | -39.70 | -- | -43.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | 64.80 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 30 Sep 2024 | 3.98k | 0.01% |
